145 related articles for article (PubMed ID: 29197875)
21. Effectiveness and Distribution of Testosterone Levels within First Year of Androgen Deprivation Therapy in a Real-World Setting: Results from the Non-Interventional German Cohort LEAN Study.
Schmitz-Dräger BJ; Mühlich S; Lange C; Benderska-Söder N; Bismarck E; Starlinger R; Ottillinger B; Hakenberg OW
Urol Int; 2021; 105(5-6):436-445. PubMed ID: 33631760
[TBL] [Abstract][Full Text] [Related]
22. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe.
Tunn UW; Wiedey K
Prostate Cancer Prostatic Dis; 2009; 12(1):83-7. PubMed ID: 19030021
[TBL] [Abstract][Full Text] [Related]
23. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
Cox MC; Scripture CD; Figg WD
Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
[TBL] [Abstract][Full Text] [Related]
24. Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer.
Merseburger AS; Roesch MC
Expert Rev Anticancer Ther; 2022 Jul; 22(7):703-715. PubMed ID: 35612551
[TBL] [Abstract][Full Text] [Related]
25. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer.
Sethi R; Sanfilippo N
Clin Interv Aging; 2009; 4():259-67. PubMed ID: 19554097
[TBL] [Abstract][Full Text] [Related]
26. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
Williams G; Lindsay S; Bowsher WG
Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
[TBL] [Abstract][Full Text] [Related]
27. Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report.
Chang JI; Bucci J
J Med Case Rep; 2016 Nov; 10(1):323. PubMed ID: 27836000
[TBL] [Abstract][Full Text] [Related]
28. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer.
Yu EY; Getzenberg RH; Coss CC; Gittelman MM; Keane T; Tutrone R; Belkoff L; Given R; Bass J; Chu F; Gambla M; Gaylis F; Bailen J; Hancock ML; Smith J; Dalton JT; Steiner MS
Eur Urol; 2015 Feb; 67(2):334-41. PubMed ID: 24968970
[TBL] [Abstract][Full Text] [Related]
29. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer.
Sharifi R; Browneller R;
J Urol; 2002 Sep; 168(3):1001-4. PubMed ID: 12187208
[TBL] [Abstract][Full Text] [Related]
30. Leuprorelin acetate granulomas: case reports and review of the literature.
Yasukawa K; Sawamura D; Sugawara H; Kato N
Br J Dermatol; 2005 May; 152(5):1045-7. PubMed ID: 15888168
[TBL] [Abstract][Full Text] [Related]
31. Is high-dose leuprorelin acetate effective and safe in asian men with prostate cancer? An open-label, non-comparative, multi-center clinical trial.
Lee SH; Lee HM; Kim SW; Lee ES; Hong SJ; Kim CS; Kang TW; Chung BH
Yonsei Med J; 2014 Mar; 55(2):310-5. PubMed ID: 24532497
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the pharmacokinetics and pharmacodynamics of two leuprolide acetate 45 mg 6-month depot formulations in patients with prostate cancer.
Mostafa NM; Chwalisz K; Larsen L; Mattia-Goldberg C; Spitz A; Pradhan RS
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):270-5. PubMed ID: 27128832
[TBL] [Abstract][Full Text] [Related]
33. Leuprorelin acetate in prostate cancer: a European update.
Persad R
Int J Clin Pract; 2002 Jun; 56(5):389-96. PubMed ID: 12137449
[TBL] [Abstract][Full Text] [Related]
34. Cost analysis of leuprorelin acetate in Japanese pre-menopausal breast-cancer patients: comparison between 6-month and 3-month depot formulations.
Goto R; Uda A; Hiroi S; Iwasaki K; Takashima K; Kurebayashi J
J Med Econ; 2017 Nov; 20(11):1163-1169. PubMed ID: 28782387
[TBL] [Abstract][Full Text] [Related]
35. ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARD
Malek R; Wu ST; Serrano D; Tho T; Umbas R; Teoh J; Lojanapiwat B; Ong TA; On WK; Thai SM; Kim J; Pophale R; Chiong E
Transl Androl Urol; 2022 Feb; 11(2):179-189. PubMed ID: 35280654
[TBL] [Abstract][Full Text] [Related]
36. An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer.
Sartor O; Dineen MK; Perez-Marreno R; Chu FM; Carron GJ; Tyler RC
Urology; 2003 Aug; 62(2):319-23. PubMed ID: 12893343
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
38. [Psychological impact of prostate cancer on patients receiving a 6-month androgen deprivation therapy].
de la Taille A; Mardoyan S; Lafaye A
Prog Urol; 2018 Jan; 28(1):32-38. PubMed ID: 29223415
[TBL] [Abstract][Full Text] [Related]
39. [Primary endocrine therapy as pre- and perimenopausal metastatic breast carcinoma with leuprorelin acetate depot. German Leuprorelin Study Group].
Untch M
Zentralbl Gynakol; 1998; 120(6):284-92. PubMed ID: 9659699
[TBL] [Abstract][Full Text] [Related]
40. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
Crawford ED; Sartor O; Chu F; Perez R; Karlin G; Garrett JS
J Urol; 2006 Feb; 175(2):533-6. PubMed ID: 16406989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
